An internal tandem duplication (ITD) of the FLT3 gene is found in nearly 20% of acute myeloid leukemia (AML) and 5% of myelodysplastic syndrome cases. Our serial studies on 51 samples with the FLT3 gene mutation indicated that the ITD was frequently (47/51) clustered in the tyrosine-rich stretch from codon 589 to 599 and rarely (3/51) in its downstream region, both of which are located within the juxtamembrane (JM) domain. One remaining sample had an insertion into the JM domain of nucleotides of unknown origin. To eludicate the biological relevance of the ITD or the insertion, we expressed various types of mutant FLT3 in Cos 7 cells. All mutant FLT3 studied were ligand-independently dimerized and their tyrosine residues were phosphorylated. The Y589 of FLT3 was essential for the phosphorylation in the wild FLT3, but a Y589F conversion did not affect the phosphorylation status of the mutant FLT3. These findings suggest that the elongation of the JM domain rather than increase of tyrosine residues causes gainof-function of FLT3. Thus, ITD is a novel modality of somatic mutation which activates its product. Since the DNA corresponding to codon 593 to 602 potentially forms a palindromic intermediate, we propose that a DNA-replication error might be associated with generating the ITD of the FLT3 gene.
Introduction
FLT3, a classs III receptor tyrosine kinase (RTK), along with KIT, FMS and PDGF-R, has an extracellular region composed of five immunoglobulin-like domains, a single transmembrane region, a juxtamembrane (JM) domain, two tyrosine kinase domains (TK1 and TK2) spaced by a kinase insert domain, and a C-terminal domain.
1,2 FLT3 is preferentially expressed in early hematopoietic progenitors in addition to the central nervous system, placenta and liver. 2, 3 FLT3 is activated by its ligand (FL) which is expressed as a membrane-bound or soluble form by bone marrow stroma cells. 4 FLT3 molecules are dimerized by the FL-binding, and are phosphorylated on its intracellular tyrosine residues. The phosphorylated FLT3 transduces activation signals through association with various cytoplasmic proteins, including RAS GTPase-activating protein, phospholipase C-␥, Vav, Shc, Cbl, Grb2 and Src family tyrosine kinases. [5] [6] [7] Most clinical samples from acute myeloid leukemia (AML) and pre-B acute lymphoblastic leukemia (ALL) also express FLT3. Exogenous FL stimulates the proliferation of AML cells rather than ALL cells, although the mechanism of different responsiveness has been little elucidated. 7, 8 gene (FLT3/ITD) was found in AML. 9 In FLT3/ITD, a fragment of the JM domain-coding sequence, which primarily consisted of exon 11 but sometimes included intron 11 and exon 12, was arranged as a direct head-to-tail succession. Its location and length varied from sample to sample, but the duplicated sequence was always in frame. [9] [10] [11] Thus, mutant FLT3 contained a long JM domain although other domains were unaffected. Clinically, FLT3/ITD was observed in nearly 20% of de novo AML cases regardless of the French-American-British (FAB) classification and in 5% of myelodysplastic syndrome (MDS) cases. 11 Its presence was related to leukocytosis in the M3 subtype of AML.
10 FLT3/ITD emerged during progression of MDS 12 or at relapse of AML (unpublished data), suggesting an association with leukemia progression rather than initiation. Although FLT3/ITD is one of the most frequent gene mutations found in acute myeloid leukemia, mutant FLT3 products and their biological significance have not been characterized.
In this study, we summarized the FLT3 gene mutations from a total of 51 AML and MDS samples. To elucidate the biological relevance of the mutations, we analyzed the expression and phosphorylation of mutant FLT3 transfected in Cos 7 cells. We showed that elongation of the JM sequence was important to gain-of-function of FLT3. Thus, this is the first report to show that ITD is a novel modality of somatic mutation which elongates the critical sequences of proto-oncogene and activates its product.
Materials and methods

Leukemia samples and detection of FLT3/ITD
High molecular weight DNA was extracted from leukemia cells, and a DNA fragment covering the JM domain was amplified by polymerase chain reaction (PCR) as previously described. 10 Abnormal sized-bands were cut out from the agarose gel, purified with a Qiaex gel extraction kit (Qiagen, Chatsworth, CA, USA), and cloned into the pMOSBlue T-vector (Amersham, Bucks, UK) as recommended by the manufacturer. Ten recombinant colonies were chosen and cultured in LB medium. Plasmid DNA was prepared using a QIAprep spin plasmid miniprep kit (Qiagen), and both strands were sequenced using fluorescein-conjugated 21M13 and T7 primers on a DNA sequencer (377; Applied Biosystems, Foster City, CA, USA). Expression of the FLT3 transcripts was examined using the reverse transcriptase-mediated PCR (RT-PCR) method as previously described. 10 Abnormal-sized products were cloned and sequenced as above to confirm that the transcript was in-frame.
Analysis of transfectants
A MunI-EcoRV fragment covering the tandem repeat of the mutated FLT3 cDNA was amplified from leukemia cells by RT-PCR using the following primer pairs: MunI-F (5′-CAA-CAATTGGTGTTTGTCTCCTCTT-3′) and EcoRV-R (5′-CATGA-TATCTCGAGCCAATCCAAAG-3′). Amplified products were digested by a combination of MunI and EcoRV endonucleases (Boehringer Mannheim Yamanouchi, Tokyo, Japan), separated on an agarose gel, and purified as described above. The expression vector pCDHF3, which contains a full-length cDNA of the FLT3 gene, was kindly provided by Dr Oliver Rosnet (INSERM, France). A fragment from the 1640 nt to the 2503 nt was removed by MunI and EcoRV digestion. The purified mutated fragment was cloned into the digested pCDHF3 vector at the MunI and EcoRV sites.
Point mutations which changed tyrosine residues Y589 and Y591 to phenylalanine residues were introduced into the wild and mutated FLT3 sequence cloned into the pCDHF3 vector with the oligonucleotides 5′-CCTCAGATAATGAGTTCTT-CTACGTTGATTTCAG-3′ and 5′-CTGAAATCAACGTAGAA-GAACTCATTATCTGAGG-3′ for Y589F and 5′-CCTCAGA-TAATGAGTACTTCTTCGTTGATTTCAG-3′ and 5′-CTGAAAT-CAACGAAGAAGTACTCATTATCTGAGG-3′ for Y591F using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). All constructs were confirmed by sequencing.
The wild and mutated constructs were transfected to Cos 7 cells by Lipofection (Gibco BRL, Gaithersburg, MD, USA) according to the manufacturer's instructions. After 72 h culture, cells were lysed in lysed buffer: 20 mM Tris-Hcl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate (SDS), 50 mM NaF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM Na 3 VO 4 , 50 mM Na 2 MoO 4 and 1 mM phenylmethylsulfonyl fluoride (PMSF). After incubation for 1 h at 4°C, lysates were spun at 15 000 g at 4°C for 30 min, and pellets were discarded. To study the effect of FL, cells were stimulated by FL at a concentration of 50 ng/ml for 10 min, then lysed as above. A portion of the lysed samples separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and electroblotted on to Immobilon PVDF membranes (Millipore, Bedford, MA, USA). The membranes were blocked overnight at 4°C in 1% blocking reagent (Boehringer Mannheim Yamanouchi) in 0.1 M maleic acid and 0.15 M NaCl, pH 7.5, and incubated in mouse anti-phosphotyrosine antibody (PY-20; Takara, Kyoto, Japan or 4G10; Upstate Biotechnology, Lake Placid, NY, USA) for 1 h, then in HRPlabeled goat anti-mouse IgG antibody (BioRad, Hercules, CA, USA) for 1 h. Signals were developed using ECL chemiluminescent reagents (Amersham). After developing the signal, we incubated the membrane in stripping buffer (62.5 mM TrisHCl, pH 6.8, 2% SDS and 100 mM 2-mercaptoethanol) at 70°C for 30 min, and reprobed it with rabbit anti-human FLT3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h, then HRP-labeled goat anti-rabbit IgG antibody (BioRad) for 1 h. The remaining lysates were incubated with anti-FLT3 antibody and precipitated with protein A/G Plusagarose (Santa Cruz Biotechnology). The precipitated samples were separated and electroblotted. The membrane was probed with anti-phosphotyrosine antibody, then reprobed with anti-FLT3 antibody as described above.
Chemical cross-linking
Dimerization of FLT3 was analyzed by chemical cross-linking. Cos 7 cells were transfected with wild and mutated FLT3 as described above, and cultured for 72 h. The transfected cells were incubated with or without FL (50 ng/ml) for 90 min at 4°C, and were washed five times in ice-cold PBS. Cross-linking was performed in PBS with BS 3 (1 mM) for 30 min at 22°C. The reaction was stopped by adding glycine-HCl (pH 7.5) to the final concentration of 150 mM and incubating for 5 min. Sodium orthovanadate (100 M) was included in all buffers. The cells were lysed, subjected to the SDS-PAGE and blotted on to the membrane as described above. The membrane was incubated in mouse anti-phosphotyrosine antibody for 1 h, then in HRPlabeled goat anti-mouse IgG antibody (BioRad) for 1 h. Signals were developed as described above. After developing the signal, the membrane was incubated in stripping buffer, and reprobed with rabbit anti-human FLT3 antibody.
Results
Individual variation of FLT3/ITD
Through our serial studies on FLT3/ITD, we have sequenced FLT3/ITD from a total of 50 AML and MDS samples. We determined which tyrosine residue(s) (denoted by Y) were involved in ITD, since the JM domain contains a Y-rich stretch, 589YFYVDFREYEY599, associated with signal transduction. In 47 of the 50 samples, all or some of these Y were duplicated in mutant FLT3; most frequently Y589/-Y591/Y597/Y599 followed by Y597/Y599. None of the samples had duplication of the fragment upsteam to Y589, but the downstream fragments were involved in five of the 50 samples. Notably, in one sample which was not reported in our previous studies, a 36-bp insertion of unknown origin was observed in exon 11 (the sequence is presented as Mt6 in Figure 1a ). These data are summarized in Table 1 .
Constitutive activation of mutant FLT3 expressed in Cos 7 cells
To analyse the phosphorylation status of mutant FLT3 it was immunoprecipitated from the clinical samples. However, significant signals were not obtained by immunoblot analysis (data not shown). Then the wild or the mutant FLT3 cDNA was transfected into Cos 7 cells. Since ITD varied from sample to sample as to position and size, six types of FLT3/ITD were chosen. Mutants 1 to 5 (Mt1-Mt5) had ITD including Y597/Y599, Y589/Y591/Y597/Y599 (long), Y589/Y591/Y597/-Y599 (short), Y591/Y597/Y599, Y589/Y591/Y597, respectively. Mutant 6 (Mt6) contained the 36 bp insertion of unknown origin (Figure 1a) .
The wild type of FLT3 was detected as a major band at 130 kDa and a minor band at 155 kDa by immunoblot analysis using total cell lysates (Figure 1b) , which corresponds to the published data. Both bands of FLT3 were immunoprecipitated with anti-FLT3 antibody and detected by immunoblot analysis. The wild type of FLT3 was significantly phosphorylated after the FL-stimulation.
Each mutant type of FLT3 was observed as the same size and the same amount of bands as the wild FLT3 by immunoblot analysis using total cell lysates (Figure 1b) . However, the anti-FLT3 antibody (anti-C-terminal 20 amino acids) failed to immunoprecipitate FLT3 from Mt1. Other mutant types of FLT3 were also precipitated to a lesser degree than the wild FLT3. These findings suggest that the mutant FLT has a conformational change of its C-terminus region. All mutant FLT3 including Mt6 were constitutively phosphorylated in a ligand-independent manner (Figure 1b) . These results indicate that FLT3 was constitutively activated by these mutations.
To study the effect of the mutant FLT3 on the wild FLT3, both FLT3 cDNA were simultaneously transfected into Cos 7 cells (Figure 1c ). Since Mt1 was not immunoprecipitated, ligand-independent phosphorylation in the transfectant indicated the phosphorylation of the wild FLT3. This finding indicates that the wild FLT3 was phosphorylated by the mutant FLT3 expressed in the same cell.
Since the dimerization of RTK is known to be a key event for the following activation, we determined whether the ITD or the insertion led to receptor dimerization without FL stimulation. Transfected Cos 7 cells were treated with BS 3 that was a hydrophilic cross-linker, 13 and FLT3 was detected by immunoblot analysis. An approximate molecular size of 260 kDa that corresponded to a probable homodimer of FLT3 was detected after the FL stimulation (Figure 2 ). On the other hand, the same sized band was detected in the mutant FLT3 without FL-stimulation. These findings suggest that the ITD or the insertion at the JM domain induced the extracellular dimerization of FLT3 without FL stimulation.
Increase of tyrosine residues is unessential for constitutive phosphorylation of FLT3
On comparing the primary structures between FLT3 and PDGF-R, the Y589 of FLT3 corresponds to Y579 of PDGF-R, which is known to be phosphorylated by ligand binding.
14 Since the phosphorylated Y579 of PDGF-R binds with the SH2 domain of the Src family, Y589 of FLT3 might similarly be associated with signal transduction. Accordingly, we next characterized the role of Y589 and Y591 in the wild or mutant type of FLT3. Using mutated oligonucleotides, Y589 and Y591 were converted to phenylalanine (denoted by Y589F and Y591F, respectively). The ligand-dependent phosphorylation was decreased in a Y589F substitution of wild FLT3, whereas it was rather enhanced in a Y591F substitution (Figure 3a) . A series of Y589F substitutions of mutant FLT3 showed constitutive phosphorylation. Similarly, a series of Y591 substitutions did not affect the phosphorylation (Figure 3b) . Thus, the increase of Y residues is not necessary and elongation of the JM domain may be more important for constitutive phosphorylation.
Discussion
In this study, we first summarized the location of FLT3/ITD from a total of 51 AML and MDS samples to assume the biological significance of FLT3/ITD. FLT3/ITD frequently involved either YFY at codons 589 to 591 or YEY at codons 597 to 599, but did not significantly affect the tyrosine-kinase domain. When we compared the primary structures between FLT3 and PDGF-R, we found the Y589 of FLT3 corresponds to Y579 of PDGFR, which is known to be phosphorylated by ligand binding. Since the phosphorylated Y579 of PDGF binds with the SH2 domain of the Src family, 14 Y589 of FLT3 might similarly be associated with signal transduction. Thus, one possibility to explain the significance of FLT3/ITD was that FLT3/ITD is associated with the amplification of FLT3 signaling. Another possibility was that FLT3/ITD causes ligand-independent activation of FLT3. Our serial studies indicated that a few samples with FLT3/ITD contain no tyrosine residue, and we also found one sample carrying an insertion of unknown origin sequence into the JM domain. Accordingly, we investigated the latter possibility in this study.
The biological significance of the ITD or the nucleotide insertion was elucidated by the Cos 7 expression system. All mutant FLT3 studied were ligand-independently phosphorylated regardless of the location and length of ITD. The mutant FLT3 with the insertion was also constitutively phosphorylated.
So far, several kinds of activating mutations have been reported in type III RTKs. Mutations of c-Kit in mast cell neoplasm are notable for their similarity to those of FLT3. Notably, the JM domain was affected; a V559G substitution and a deletion of 7 amino acids. 13, 15 Both mutant c-Kits were 
Figure 2
Cross-linking experiment. The wild or mutant FLT3 was cross-linked by BS 3 and detected by immunoblot analysis using antiphosphotyrosine antibody.
not only autophosphorylated but also dimerized between extracellular domains without ligand stimulation. On the other hand, a D814Y mutation in TK2 domain caused autonomous phosphorylation without dimerization. 16 Another member of RTK type III, PDGF, is involved in the t(5;12) translocation found in chronic myelomonocytic leukemia. The resultant TEL-PDGF fusion product was an activated mutant of PDGF, because TEL-derived sequence contributed to oligomerization of PDGF-derived sequence. 17 Thus, the constitutive dimerization is a key mechanism for activating mutation of RTK. FLT3/ITD also seems to cause ligand-independent dimerization of FLT3 for the following reasons. First, since the wild FLT3 was ligand-independently phosphorylated by the simultaneous transfection of the mutant FLT3, the mutant FLT3 must physically associate with the wild FLT3. Second, the crosslinking experiment showed that mutant FLT3 formed a highmolecular complex, presumably a dimer, on cell surface without FL stimulation. The JM domain mutations might induce an extracellular conformational change which favors dimer formation of FLT3.
To further confirm that elongation is more important for the constitutive activation than the increase of tyrosine residues,
Figure 3
The role of Y589 and Y591 in wild and mutant types of FLT3. The Y589 and Y591 were converted to phenylalanine. The precipitated samples by the anti-FLT3 antibody were detected by immunoblot analysis using anti-phosphotyrosine antibody. The ligand-dependent phosphorylation was decreased in a Y589F substitution of wild FLT3 (a). A series of Y589F substitutions of mutant FLT3 showed constitutive phosphorylation. Similarly a series of Y591 substitutions did not affect phosphorylation (b).
we substituted Y589 or Y591 for phenylalanine. It was shown that a Y589F conversion did not affect the phosphorylation status of the mutant FLT3 in contrast to the wild FLT3. Why then is the ITD clustered around Y597/Y599? What is the molecular mechanism of generating ITD? Generally, when a single-stranded DNA has the potential to form complex secondary structures including hairpins, it may be responsible for replication-based mutations: deletion, addition, frameshift and duplication. That is, hairpin formation of a lagging template or strand causes replication slippage generating DNA deletion or duplication, respectively. 18, 19 This model has been proposed to account for microsatellite instability in mutator mutants and triplet disease such as inherited neuromuscular disease. 20 We suppose it is further applicable to FLT3/ITD for the following reason. According to the sequence data from 50 samples with FLT3/ITD, duplication frequency at each tyrosine codon was as follows: 25/50 (50%) at Y589, 28/50 (56%) at Y591, 33/50 (66%) at Y597, 36/50 (72%) at Y599 (Table 1) . Additionally, F605 was involved in 22/50 (44%) (data not shown). Accordingly, Y597 and Y599 were most frequently involved in FLT3/ITD. As shown in Figure 4 , the DNA corresponding to D593 to K602 potentially forms a palindromic intermediate. If a lagging strand makes a hairpin during DNA replication and the following mismatch repair system is impaired, the tandemly duplicated fragment will be fixed in DNA. If FLT3/ITD occurs in an out-of-frame manner, the leukemia cell carrying it does not acquire a growth advantage and will not be selected. Although simple models should be inspected using various replication systems, we think the replication error is thus an underlying mechanism for FLT3/ITD.
Finally, investigation of FLT3/ITD would provide a new perspective on leukemia as to genetic instability and aberrant signal transduction, as well as leukemia progression.
